Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.56 |
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021135 | 0.82 | APP (0.64) | APPHTR2CADRB2HTR1F | |
| SCHEMBL12132005 | 0.82 | APP (0.56) | APPHTR2CADRB2HTR1F | |
| SCHEMBL12874707 | 0.82 | APP (0.56) | APPHTR2CADRB2HTR1F | |
| SCHEMBL12874810 | 0.82 | APP (0.56) | APPHTR2CADRB2CAMKK2HTR1F | |
| SCHEMBL12874689 | 0.82 | APP (0.56) | APPHTR2CADRB2HTR1F | |
| SCHEMBL12889637 | 0.81 | APP (0.53) | APPHTR2CADRB2HTR1F | |
| SCHEMBL12874786 | 0.78 | APP (0.50) | APPHTR2CADRB2HTR1FADORA2A | |
| SCHEMBL12874710 | 0.77 | APP (0.52) | APPHTR2CADRB2 | |
| SCHEMBL26775960 | 0.77 | APP (0.41) | APPPDK2PDK4CAMKK2ADORA2A | |
| SCHEMBL26775940 | 0.77 | APP (0.41) | APPPDK2PDK4CAMKK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, HRH2, PTGDR2 | APP 4427/4885HTR2C 142/4885ADRB2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.